Compound class:
Synthetic organic
Comment: The chemical structure for this MRGPRX2 antagonist was revealed during the first disclosures session at the 2022 ACS meeting in Chicago. The orphan MRGPRX GPCRs are being investigated as potential drug targets for mast cell-mediated immune diseases [1-4].
|
|
Bioactivity Comments |
We have been unable to find quantitative data that confirms the activity of this antagonist at its proposed molecular target. |